Caribou Biosciences (CRBU) Cash from Operations (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Cash from Operations of 26984000.0 for Q1 2026, up 26.52% year-over-year from 21327151.04 in Q1 2025, and down 29.78% quarter-over-quarter from 20792000.0 in Q4 2025.
Caribou Biosciences (CRBU) Cash from Operations (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Cash from Operations for 7 consecutive years, with 26984000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 26.52% year-over-year to 26984000.0; the TTM figure through Mar 2026 stood at 101251000.0 (up 26.48% YoY), while the FY2025 annual figure was 110992000.0, up 19.69% from the prior year.
- Cash from Operations declined to 26984000.0 in Q1 2026 per CRBU's latest filing, from 20792000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 15185000.0 in Q2 2023 and bottomed at 37203000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 27084294.12 across 5 years, with a median of 26984000.0 in 2026.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 206.7% — and 2025, when it soared 41.38%.
- Caribou Biosciences' Cash from Operations stood at 25044000.0 in 2022, then rose by 14.63% to 21379000.0 in 2023, then tumbled by 65.91% to 35470000.0 in 2024, then jumped by 41.38% to 20792000.0 in 2025, then dropped by 29.78% to 26984000.0 in 2026.
- Business Quant data shows CRBU's Cash from Operations at 26984000.0 in Q1 2026, 20792000.0 in Q4 2025, and 25217000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | -22.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.80 Mn |
| Jun 30, 2026 | -22.80 Mn |
| Mar 31, 2026 | -26.98 Mn |
| Mar 31, 2026 | -26.98 Mn |
| Dec 31, 2025 | -20.79 Mn |
| Dec 31, 2025 | -20.79 Mn |
| Sep 30, 2025 | -25.22 Mn |
| Sep 30, 2025 | -25.22 Mn |
| Jun 30, 2025 | -28.26 Mn |
| Jun 30, 2025 | -28.26 Mn |
| Mar 31, 2025 | -36.73 Mn |
| Mar 31, 2025 | -36.73 Mn |
| Dec 31, 2024 | -35.47 Mn |
| Dec 31, 2024 | -35.47 Mn |
| Sep 30, 2024 | -32.66 Mn |
| Sep 30, 2024 | -32.66 Mn |
| Jun 30, 2024 | -32.87 Mn |
| Jun 30, 2024 | -32.87 Mn |
| Mar 31, 2024 | -37.20 Mn |
| Mar 31, 2024 | -37.20 Mn |